Sangamo Therapeutics, Inc. (SGMOQ)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	27.59	20.95	41.92	45.2	100.44	178.87
Short-Term Investments	-	-	-	35.8	177.19	197.68
Cash & Short-Term Investments	27.59	20.95	41.92	81	277.63	376.55
Cash Growth	9.55%	-50.03%	-48.25%	-70.82%	-26.27%	-41.30%
Accounts Receivable	0.87	0.37	0.53	0.92	3.68	6.01
Other Receivables	5.49	10.14	4.07	3.14	0.79	0.35
Receivables	6.36	10.51	4.6	4.07	4.47	6.36
Prepaid Expenses	3.16	4.37	5.18	9.26	18.22	15.86
Total Current Assets	37.11	35.83	51.69	94.33	300.33	398.77
Property, Plant & Equipment	13.22	14.11	34.76	52.87	125.53	124.7
Long-Term Investments	-	-	-	-	29.85	88.17
Goodwill	-	-	-	-	37.55	39.7
Other Intangible Assets	-	-	-	-	50.73	53.76
Long-Term Deferred Tax Assets	-	-	-	-	1.12	1.06
Other Long-Term Assets	9.63	9.81	15.19	18.13	17.41	15.76
Total Assets	59.97	59.75	101.64	165.32	562.51	721.92

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	19.31	14.44	15.49	15.26	22.42	9.76
Accrued Expenses	33.43	25.43	17.56	16.15	33.39	28.39
Current Portion of Leases	-	1.7	4.31	4.59	4.12	4.03
Current Unearned Revenue	0.4	0.9	7.56	-	51.78	85.71
Other Current Liabilities	-	-	0.9	11.73	-	-
Total Current Liabilities	53.13	42.47	45.81	47.73	111.71	127.89
Long-Term Leases	19.33	25.09	26.25	33.52	38.99	44.06
Long-Term Unearned Revenue	5.87	5.87	5.87	-	109.38	166.78
Long-Term Deferred Tax Liabilities	-	-	-	-	6.27	6.65
Other Long-Term Liabilities	0.58	0.58	0.93	1.19	1.21	1.22
Total Liabilities	78.92	74.01	78.87	82.43	267.55	346.58

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	4.14	3.51	2.13	1.78	1.67	1.46
Additional Paid-In Capital	1,638	1,611	1,532	1,492	1,450	1,334
Retained Earnings	-1,658	-1,627	-1,504	-1,406	-1,149	-956.27
Comprehensive Income & Other	-2.51	-1.46	-7.53	-4.6	-8.4	-3.99
Total Common Equity	-18.96	-14.27	22.77	82.89	294.96	375.34
Shareholders' Equity	-18.96	-14.27	22.77	82.89	294.96	375.34
Total Liabilities & Equity	59.97	59.75	101.64	165.32	562.51	721.92

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	19.33	26.8	30.57	38.1	43.11	48.08
Net Cash (Debt)	8.25	-5.85	11.35	42.9	264.37	416.64
Net Cash Growth	2615.13%	-	-73.54%	-83.77%	-36.55%	-35.89%
Net Cash Per Share	0.03	-0.02	0.06	0.25	1.71	2.88
Filing Date Shares Outstanding	414.29	414.27	224.71	178.91	168.48	145.97
Total Common Shares Outstanding	414.27	350.69	212.84	178.13	166.79	145.92
Working Capital	-16.02	-6.64	5.89	46.6	188.62	270.88
Book Value Per Share	-0.05	-0.04	0.11	0.47	1.77	2.57
Tangible Book Value	-18.96	-14.27	22.77	82.89	206.68	281.88
Tangible Book Value Per Share	-0.05	-0.04	0.11	0.47	1.24	1.93
Machinery	-	31.42	32.78	47.02	54.72	49.85
Construction In Progress	-	-	-	1.09	14.77	4.73
Leasehold Improvements	-	21.83	24.92	29.81	30.57	21.97

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 29, 2026

Data Sources Report a data error